

Clarification regarding HOPE™ Distribution to Washington DC, USA

18 December 2020

Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the development of clinically validated cannabis medicines, advises the following clarification in relation to the ASX announcement 'Zelira Therapeutics Expands HOPE™ Distribution to Washington DC, USA' dated 14 December 2020.

Zelira wished to advise the following:

- Zelira does not consider the upfront fee to be material. The royalty of course has the potential to be material, but it is to be based on sales, and therefore the Company has no reasonable method of quantifying that amount.
- The contract can be terminated if Net Sales of the Products for any four consecutive Quarterly Periods beginning with the fourth Quarterly period after the Effective Date of first product sale are less than Two hundred and fifty thousand US Dollars (US\$250,000).
- Two years, automatically renewable yearly, at upon the mutual consent of both parties, for an additional three-year term. There are no conditions precedent that remain unsatisfied.

DISCLOSURES:

This announcement has been approved and authorised for release by the board of Zelira Therapeutics Limited.

Oludare Odumosu

Managing Director USA

About Zelira Therapeutics (www.zeliratx.com)

Zelira Therapeutics Ltd is a leading global therapeutic medical cannabis company with access to the world's largest and fastest growing cannabis markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020. The company is focused on developing branded cannabis products for the treatment of a variety of medical conditions.

The Company is undertaking product development programs targeting specific conditions and human clinical trial programs focused on insomnia, autism and opioid reduction in patients with chronic non-cancer pain.

The Company has developed two proprietary formulations (HOPE™) targeting Autism Spectrum Disorder already launched and generating revenues in Pennsylvania and Louisiana and Australia. Zelira has also launched Zenivol™ in Australia as the worlds leading clinically validated proprietary formulation for treatment of chronic insomnia.

The Company conducts this work in partnership with world-leading researchers and organizations including Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in

Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States.

About Alternative Solutions (www.altsol.co)

Montana Apocathary d/b/a Alternative Solutions is one of eight current license holders for the cultivation, processing and distribution of cannabis within the District of Columbia. Alternative Solutions is licensed to distribute medical cannabis products to all seven licensed MMJ dispensaries within the District. Operational since 2015, Alternative Solutions focuses on providing a consistent supply of premium products to all licensed dispensaries in DC.

Address

Level 26
140 St Georges Terrace
Perth WA 6000
AUSTRALIA
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeliratx.com
W: www.zeliratx.com
ACN 103 782 378

Tickers

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Australia Contacts:

Dr. Richard Hopkins
Managing Director & CEO, Ex USA
+61 405 656 868
rhopkins@zeliratx.com
Level 26, 140 St Georges Terrace
Perth WA 6000
AUSTRALIA

Monsoon Communications

Rudi Michelson
+61 3 9620 3333
rudim@monsoon.com

U.S. Contacts:

Dr. Oludare Odumosu
Managing Director & CEO, USA
+1 909 855 0675
oodumosu@zeliratx.com
3553 West Chester Pike #110
Newtown Square PA 19073
UNITED STATES OF AMERICA

GVM Communications, Inc.

Gia Morón
+1 347 678 8079
gia@gvmcommsinc.com